AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04364269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 once a day (QD)
Description: Participants will receive VIT-2763 QD at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
Study NCT03785145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected into the LCL.
Study NCT03105336 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: axicabtagene ciloleucel
Description: A single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered intravenously.
Study NCT03105336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously
Study NCT04364269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 twice a day (BID)
Description: Participants will receive VIT-2763 BID at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
Study NCT04364269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive hard capsules of Placebo, twice a day.
Study NCT04963049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol with Mask
Description: Look at differences in group with facemask and no mask
Study NCT01387113 — intervention group
Intervention type: OTHER
Intervention: Computed tomography perfusion imaging
Description: As per standard of care at CPMC
Study NCT02824679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: 0.9%normal saline
Study NCT02824679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 0.9%normal saline
Study NCT04173572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE-Life
Description: PACE-Life Groups will occur twice per week for 15 minutes in the first two weeks, progressing to 30-minute walking sessions over the course of the intervention without changes in frequency. The intensity of virtual walks will increase throughout this intervention in a stepwise fashion to create an exercise dose response to maximize impact on CRF.
Study NCT04173572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Data from Fitbit devices will be synced and accessed through Fitbit.com. Participants will be provided account information to view data but will be asked not to change any of the settings as the investigators will be using data for tracking steps/day and minutes spent walking.
Study NCT03844854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization occlusal splint and manual therapy
Description: Providing stabilization occlusal splint and manual therapy
Study NCT00576888 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention - observational only
Study NCT00078962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04228692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self-catheterization only
Description: Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.
Study NCT04228692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation + self-catheterization
Description: Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.~Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary.
Study NCT02255851 — intervention group
Intervention type: DEVICE
Intervention: SENTINEL (Cerebral Protection System)
Study NCT00760422 — intervention group
Intervention type: DEVICE
Intervention: NIR
Description: Thermometer
Study NCT03977285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
Study NCT03977285 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
Study NCT03977285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
Study NCT02934412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
Study NCT02934412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
Study NCT00585455 — intervention group
Intervention type: DRUG
Intervention: sertraline
Description: open label 25-50 mg daily as tolerated
Study NCT03105336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study NCT03316326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium
Description: 40 mg bid, D1-14
Study NCT03316326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2, D1
Study NCT03758950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily inhaled placebo for 48 weeks
Study NCT03758950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone
Description: Inhaled Mometasone for 48 weeks (with 4-week washout at study completion)
Study NCT05739513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: miRNA analysis in plasma
Description: blood sample
Study NCT03316326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m2, D8
Study NCT04100096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Tablet
Study NCT04100096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT04065061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Erinacine A-enriched Hericium Erinaceus Mycelia
Study NCT04065061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement was given to the participants.
Study NCT02741154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction with aromataze inhibitor
Description: letrozole 2.5mg once daily start in the first day of menses for 5days
Study NCT02741154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMG
Description: HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
Study NCT02741154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMG
Description: HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
Study NCT02001519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC4-CDDP4
Description: 4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks 4 cycles of cisplatin 75 mg/m2 every 3 weeks
Study NCT03419208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPIN-HAND Program
Description: The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
Study NCT03393104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Control Exercise
Description: Activation of specific muscles of the lumbopelvic region responsible for providing stability or control of posture and movement.
Study NCT03393104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Education aiming to change unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.
Study NCT01466088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Subjects taking donepezil will take 1-2 capsules of 5 mg donepezil and a placebo for AZD3480 (to maintain blind) orally once a day.
Study NCT01466088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: Subjects taking 30 mg AZD3480 will take one capsule of AZD3480 and two capsules of placebo for donepezil (to maintain blind) orally once a day.
Study NCT03761966 — intervention group
Intervention type: OTHER
Intervention: Pregnant women
Study NCT03908424 — intervention group
Intervention type: OTHER
Intervention: Epidural Blood patch.
Description: An epidural blood patch is a surgical procedure that uses autologous blood in order to close one or many holes in the dura mater of the spinal cord, usually as a result of a previous lumbar puncture. A small amount of the patient's blood is injected into the epidural space near the site of the original puncture; the resulting blood clot then patches the meningeal leak. An epidural needle is inserted into the epidural space at the site of the cerebrospinal fluid leak and blood is injected. The clotting factors of the blood close the hole in the dura.
Study NCT02741154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRh a
Description: antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection
Study NCT02741154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRh a
Description: antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection
Study NCT02741154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG
Description: 10.000 IU HCG injection when at least three follicles reach 17mm in diameter
Study NCT02741154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG
Description: 10.000 IU HCG injection when at least three follicles reach 17mm in diameter
Study NCT03668431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be taken twice a day for 28 consecutive days~.
Study NCT03668431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be taken once a day for 28 consecutive days
Study NCT03668431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 will be administered IV every 28 days
Study NCT02277431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic dietary supplement (Trenev Trio®)
Description: Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am \& pm) offering a total daily serving of:~* Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units \[CFU\])~* Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~* Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)
Study NCT02277431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02400476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Study NCT02400476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Study NCT02400476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colestipol
Description: 2 g twice daily with or without food for one 28 day cycle
Study NCT02400476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 9 mg extended release tablets once daily with or without food for 28 days
Study NCT00965016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hypothermia
Description: Core temperature --> 34.9℃ within 30 min --> 33.5℃ within 120min --> 33℃for 24 H Decrease temperature in 0.9℃/hour
Study NCT00965016 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: hypothermia
Description: Core temperature --> 34.9℃ within 30 min --> 33.5℃ within 120min --> 33℃for 24 H Decrease temperature in 0.9℃/hour
Study NCT03536182 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Ion Radiation Therapy (CIRT)
Description: Patient will receive CIRT daily, 4 days a week for a total of 12 fractions/treatments plus concurrent chemotherapy (gemcitabine) weekly for 3 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic. Within 6 weeks of completing radiotherapy, patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
Study NCT03536182 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Patient will receive IMRT daily, 5 days a week for a total of 28 fractions/treatments plus concurrent chemotherapy (gemcitabine or capecitabine) weekly for 5 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic,within 6 weeks of completing radiotherapy,patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
Study NCT03928535 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High-FlowNasal Cannula
Description: High-flowoxygenwas applied immediately after extubation through specific nasal cannula. Flow was initially set at 10 L/min and titrated upwards in 5-L/min steps until patients experienced discomfort.Temperature was initially set to 37°C, unless reported too hot by patients, and FIO2 was regularly adjusted to the target peripheral capillary oxygen saturation (SPO2) of greater than 92%. After 24 hours, high-flow was stopped and, if necessary, patients received conventional oxygen therapy.
Study NCT03928535 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Noninvasive Ventilation
Description: Full face mask NIV was continuously delivered immediately after extubation for a scheduled period of 24 hours after extubation. Afterward, NIV was withdrawn and oxygen was administered by Venturi mask.Both PEEP and inspiratory pressure supportwere adjusted to target a respiratory rate of 25/min and adequate gas exchange (arterial oxygen saturation \[SaO2\] 92%, with pH of 7.35). The FIO2 was adjusted to maintain SPO2 at less than 92%. Sedatives to increase tolerance to NIV were not allowed.
Study NCT02693756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks.
Study NCT01413815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: 3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).
Study NCT01413815 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)
Study NCT01242462 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Pressure Controlled SIMV
Description: Initial ventilatory settings per clinical physician's discretion-tcCO2 \& Saturation (SAT) monitoring. Adjust vent setting approximately every 15min with a goal of: SAT 88-95%, tcCO2 45-55, pH greater than or equal to 7.25. Once goals reached, ventilatory strategy will crossed over to other intervention.
Study NCT02100826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Administered orally.
Study NCT02100826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Administered orally.
Study NCT01939145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies
Study NCT01939145 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prontosan
Description: Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.
Study NCT03429088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing telephone counseling
Study NCT04557488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Each session will follow a similar structure with a hello song, musical activities, and a goodbye song. The musical activities will vary in each session and will be mixed in later sessions to revisit and practice social skills
Study NCT04557488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral-based social skill training
Description: Each intervention session will follow a standard structure of opening greetings, social activities according to the theme of the session, and a closing activity. The activities and games will vary in each session and will be mixed in later session to revisit and practice social skills.
Study NCT02886897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-CIK and anti-PD-1 antibody
Description: Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5\*10\^10 cells)were incubated with anti-PD-1 antibody and infused into participants.
Study NCT00807430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grindcare (Active)
Description: Active treatment
Study NCT00807430 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Grindcare (Placebo - the device is not activated)
Description: Placebo treatment
Study NCT01003223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer algorithm management of hyperphosphatemia
Description: The PKM algorithm is a computer based program that calculates Phosphorus intake between dialysis, phosphorus reduction during dialysis treatment and daily oral phosphate binder intake compliance. Based on pre and post dialysis serum phosphorus levels, the algorithm makes recommendations in relation to dialysate calcium, oral phosphate binder use, and dietary counseling.
Study NCT02692573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positioning
Description: prone positioning for the initial 5 minutes of life
Study NCT02692573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: positioning
Description: supine positioning for the initial 5 minutes of life